Antonio Calles, Head of the Lung Cancer Unit at Ruber International Hospital, shared a post on X:
“Randomized phase Il trial of tobemstomig (bi-specific PD1xLAG3) + platinum-based chemo vs pembrolizumab + chemo in 1L NSCLC. Presented by Ernest Nadal.
Negative trial not supporting LAG-3 combination in NSCLC.”
